HRP20210641T1 - Deuterirani heterociklični spojevi i njihova uporaba kao sredstva za kontrastiranje - Google Patents
Deuterirani heterociklični spojevi i njihova uporaba kao sredstva za kontrastiranje Download PDFInfo
- Publication number
- HRP20210641T1 HRP20210641T1 HRP20210641TT HRP20210641T HRP20210641T1 HR P20210641 T1 HRP20210641 T1 HR P20210641T1 HR P20210641T T HRP20210641T T HR P20210641TT HR P20210641 T HRP20210641 T HR P20210641T HR P20210641 T1 HRP20210641 T1 HR P20210641T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- individual
- deuterated
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000012216 imaging agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 16
- 102000013498 tau Proteins Human genes 0.000 claims 10
- 108010026424 tau Proteins Proteins 0.000 claims 10
- 208000037259 Amyloid Plaque Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 230000002285 radioactive effect Effects 0.000 claims 6
- 208000012902 Nervous system disease Diseases 0.000 claims 5
- 238000005259 measurement Methods 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Claims (18)
1. Deuterirani spoj s izotopom za kontrastiranje, naznačen time, da spoj ima formulu (Ie):
[image]
i naznačen time, da ugljik označen zvjezdicom * ima faktor izotopskog obogaćenja deuterija od najmanje 3500.
2. Deuterirani spoj s izotopom za kontrastiranje, naznačen time, da ima formulu (Ie):
[image]
ili njegova sol.
3. Deuterirani spoj s izotopom za kontrastiranje, naznačen time, da se spoj bira između:
[image]
[image]
[image]
[image]
i njihovih soli.
4. Farmaceutski pripravak, naznačen time da sadrži deuterirani spoj prema bilo kojem patentnom zahtjevu od 1 do 3 ili njegovu farmaceutski prihvatljivu sol te farmaceutski prihvatljivo otapalo ili nosač.
5. Postupak za otkrivanje neurofibrilarnih čvorova i/ili senilnih plakova kod pojedinca, naznačen time, da obuhvaća
- davanje pojedincu deuteriranog spoja s izotopom za kontrastiranje, kako je opisan u bilo kojem od patentnih zahtjeva od 1 do 3, ili njegove farmaceutski prihvatljive soli,
- i mjerenje radioaktivnog signala spoja.
6. Postupak prema patentnom zahtjevu 5, naznačen time, da se mjerenje vrši putem gama scintigrafije.
7. Postupak otkrivanja neurološkog poremećaja povezanog s amiloidnim plakom i/ili nakupljanjem tau proteina kod pojedinca, naznačen time, da obuhvaća
- davanje pojedincu deuteriranog spoja s izotopom za kontrastiranje, kako je opisan u bilo kojem od patentnih zahtjeva od 1 do 3, ili njegove farmaceutski prihvatljive soli, u količini koju je moguće detektirati,
- i mjerenje radioaktivnog signala spoja povezanog s amiloidnim naslagama i/ili agregatima tau proteina.
8. Postupak otkrivanja Alzheimerove bolesti kod pojedinca, naznačen time, da obuhvaća
- davanje pojedincu deuteriranog spoja s izotopom za kontrastiranje, kako je opisan u bilo kojem od patentnih zahtjeva od 1 do 3 ili njegove farmaceutski prihvatljive soli, u količini koju je moguće detektirati, i
- nakon što se spoj poveže s amiloidnim naslagama i/ili tau proteinima, mjerenje radioaktivnog signala spoja povezanog s amiloidnim naslagama i/ili agregatima tau proteina.
9. Postupak otkrivanja Alzheimerove bolesti, naznačen time, da obuhvaća
- davanje pojedincu deuteriranog spoja prema bilo kojem od patentnih zahtjeva od 1 do 3 ili njegove farmaceutski prihvatljive soli, u količini koju je moguće detektirati, i
- nakon što se kod pojedinca spoj poveže s agregatima tau proteina, mjerenje radioaktivnog signala spoja povezanog s agregatima tau proteina.
10. Deuterirani spoj, kako je opisan u bilo kojem od patentnih zahtjeva od 1 do 3, ili njegova farmaceutski prihvatljiva sol za primjenu u medicinskoj dijagnostici neuroloških poremećaja.
11. Deuterirani spoj, kako je opisan u bilo kojem od patentnih zahtjeva od 1 do 3, ili njegova farmaceutski prihvatljiva sol za primjenu u otkrivanju neurofibrilarnih čvorova i/ili senilnih plakova u dijagnostici neuroloških poremećaja.
12. Deuterirani spoj, kako je opisan u bilo kojem od patentnih zahtjeva od 1 do 3, ili njegova farmaceutski prihvatljiva sol za primjenu u dijagnostici neurološkog poremećaja.
13. Deuterirani spoj, kako je opisan u bilo kojem od patentnih zahtjeva od 1 do 3, ili njegova farmaceutski prihvatljiva sol za primjenu u dijagnostici Alzheimerove bolesti.
14. Uporaba deuteriranog spoja, kako je opisan u bilo kojem od patentnih zahtjeva od 1 do 3, ili njegove farmaceutski prihvatljive soli, za pripremu medikamenta za otkrivanje neurofibrilarnih čvorova i/ili senilnih plakova kod pojedinca.
15. Uporaba deuteriranog spoja, kako je opisan u bilo kojem od patentnih zahtjeva od 1 do 3, ili njegove farmaceutski prihvatljive soli, za pripremu medikamenta za otkrivanje neurološkog poremećaja kod pojedinca.
16. Uporaba deuteriranog spoja, kako je opisan u bilo kojem od patentnih zahtjeva od 1 do 3, ili njegove farmaceutski prihvatljive soli, za pripremu medikamenta za otkrivanje Alzheimerove bolesti kod pojedinca.
17. Postupak otkrivanja progresivne supranuklearne paralize kod pojedinca, naznačen time, da obuhvaća
- davanje pojedincu deuteriranog spoja prema bilo kojem od patentnih zahtjeva od 1 do 3 ili njegove farmaceutski prihvatljive soli, u količini koju je moguće detektirati, i
- nakon što se spoj veže za amiloidni plak i/ili agregate tau proteina, mjerenje radioaktivnog signala spoja povezanog s amiloidnim naslagama i/ili agregatima tau proteina.
18. Postupak otkrivanja progresivne supranuklearne paralize, naznačen time da obuhvaća
- davanje deuteriranog spoja prema bilo kojem od patentnih zahtjeva od 1 do 3 ili njegove farmaceutski prihvatljive soli, u količini koju je moguće detektirati, i
- nakon što se spoj veže za agregate tau proteina, mjerenje radioaktivnog signala spoja povezanog s agregatima tau proteina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992717P | 2014-05-13 | 2014-05-13 | |
| PCT/EP2015/060447 WO2015173225A1 (en) | 2014-05-13 | 2015-05-12 | Deuterated heterocyclic compounds and their use as imaging agents |
| EP15725253.7A EP3143011B1 (en) | 2014-05-13 | 2015-05-12 | Deuterated heterocyclic compounds and their use as imaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210641T1 true HRP20210641T1 (hr) | 2021-05-28 |
Family
ID=53269446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210641TT HRP20210641T1 (hr) | 2014-05-13 | 2021-04-22 | Deuterirani heterociklični spojevi i njihova uporaba kao sredstva za kontrastiranje |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10076581B2 (hr) |
| EP (2) | EP3143011B1 (hr) |
| JP (2) | JP6529986B2 (hr) |
| KR (2) | KR102618139B1 (hr) |
| CN (2) | CN110483522B (hr) |
| AU (2) | AU2015261008B2 (hr) |
| CA (1) | CA2948721C (hr) |
| DK (1) | DK3143011T3 (hr) |
| ES (1) | ES2867814T3 (hr) |
| HR (1) | HRP20210641T1 (hr) |
| HU (1) | HUE053939T2 (hr) |
| IL (3) | IL280791B2 (hr) |
| LT (1) | LT3143011T (hr) |
| MX (2) | MX2020010847A (hr) |
| PL (1) | PL3143011T3 (hr) |
| PT (1) | PT3143011T (hr) |
| RS (1) | RS61810B1 (hr) |
| RU (1) | RU2696492C2 (hr) |
| SG (2) | SG10201805628TA (hr) |
| SI (1) | SI3143011T1 (hr) |
| WO (1) | WO2015173225A1 (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201805628TA (en) * | 2014-05-13 | 2018-08-30 | Hoffmann La Roche | Deuterated heterocyclic compounds and their use as imaging agents |
| JP7059270B2 (ja) | 2016-07-22 | 2022-04-25 | エーシー・イミューン・エス・アー | タウタンパク質凝集体を画像化するための化合物 |
| KR102472003B1 (ko) | 2016-07-22 | 2022-11-29 | 에이씨 이뮨 에스에이 | 타우 단백질 응집체를 이미징하기 위한 화합물 |
| CA3042260C (en) * | 2016-11-01 | 2023-10-03 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| IL272838B2 (en) | 2017-10-06 | 2023-09-01 | Forma Therapeutics Inc | Peptidase-specific ubiquitin inhibition 30 |
| WO2019145291A1 (en) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Gamma-carboline compounds for the detection of tau aggregates |
| US20210041447A1 (en) | 2018-01-24 | 2021-02-11 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| EP3758696A4 (en) | 2018-03-02 | 2021-12-08 | The Trustees of the University of Pennsylvania | [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AND USE OF THESE IN THE STABILIZATION OF MICROTUBULES |
| SG11202011299PA (en) | 2018-05-17 | 2020-12-30 | Forma Therapeutics Inc | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
| CA3113234A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| HUE066335T2 (hu) | 2018-10-05 | 2024-07-28 | Annapurna Bio Inc | Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére |
| PE20211053A1 (es) | 2018-10-05 | 2021-06-07 | Forma Therapeutics Inc | Inhibicion de la proteasa 30 especifica de la ubiquitina (usp30) |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| JP7119978B2 (ja) * | 2018-12-20 | 2022-08-17 | オムロン株式会社 | 制御装置およびプログラム |
| EP3966215A1 (en) * | 2019-05-09 | 2022-03-16 | F. Hoffmann-La Roche AG | Synthesis of labeled imidazo[1,2-a]pyrimidines |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| CN113526526A (zh) * | 2021-07-12 | 2021-10-22 | 苏州大学 | 氘代氨制备方法及以其作为氘源参与的氘代反应 |
| AU2022332303A1 (en) | 2021-08-27 | 2024-02-01 | Genentech, Inc. | Methods of treating tau pathologies |
| WO2023245008A1 (en) | 2022-06-13 | 2023-12-21 | Genentech, Inc. | Methods of delaying or preventing the onset of alzheimer's disease using crenezumab |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE76515C (de) | F. MORA in Mailand | Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff | ||
| DD76515A (hr) * | ||||
| EP1340759A1 (en) | 2002-02-28 | 2003-09-03 | Sanofi-Synthelabo | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
| US6875784B2 (en) | 2002-10-09 | 2005-04-05 | Pharmacia & Upjohn Company | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives |
| CN101522624B (zh) | 2006-03-30 | 2013-11-06 | 宾夕法尼亚大学理事会 | 苯乙烯基吡啶衍生物及其用于结合和成像淀粉样蛋白斑的用途 |
| CA2698808A1 (en) * | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
| US8932557B2 (en) | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
| LT2247558T (lt) | 2008-02-14 | 2022-04-11 | Eli Lilly And Company | Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui |
| US20100144657A1 (en) * | 2008-12-09 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS |
| CN102438660A (zh) | 2009-03-23 | 2012-05-02 | 美国西门子医疗解决公司 | 用于检测神经障碍的显像剂 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| EP2450332A1 (en) * | 2010-10-22 | 2012-05-09 | Bayer Pharma Aktiengesellschaft | Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl) |
| BR112013011737A2 (pt) * | 2010-11-15 | 2016-08-09 | Univ Leuven Kath | composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv |
| ES2792830T3 (es) * | 2012-05-22 | 2020-11-12 | Lilly Co Eli | Agentes para formación de imagen en base a carbolina y carbazol, para la detección de disfunción neurológica |
| SG11201602786UA (en) * | 2013-10-08 | 2016-05-30 | Hoffmann La Roche | Diazacarbazole derivatives as tau-pet-ligands |
| SG10201805628TA (en) | 2014-05-13 | 2018-08-30 | Hoffmann La Roche | Deuterated heterocyclic compounds and their use as imaging agents |
-
2015
- 2015-05-12 SG SG10201805628TA patent/SG10201805628TA/en unknown
- 2015-05-12 RU RU2016147742A patent/RU2696492C2/ru active
- 2015-05-12 EP EP15725253.7A patent/EP3143011B1/en active Active
- 2015-05-12 HU HUE15725253A patent/HUE053939T2/hu unknown
- 2015-05-12 SG SG11201609281UA patent/SG11201609281UA/en unknown
- 2015-05-12 MX MX2020010847A patent/MX2020010847A/es unknown
- 2015-05-12 ES ES15725253T patent/ES2867814T3/es active Active
- 2015-05-12 RS RS20210532A patent/RS61810B1/sr unknown
- 2015-05-12 CN CN201910795177.8A patent/CN110483522B/zh active Active
- 2015-05-12 IL IL280791A patent/IL280791B2/en unknown
- 2015-05-12 WO PCT/EP2015/060447 patent/WO2015173225A1/en active Application Filing
- 2015-05-12 EP EP21155891.1A patent/EP3901145A1/en active Pending
- 2015-05-12 SI SI201531590T patent/SI3143011T1/sl unknown
- 2015-05-12 CN CN201580025219.XA patent/CN106459059B/zh active Active
- 2015-05-12 KR KR1020237006997A patent/KR102618139B1/ko active IP Right Grant
- 2015-05-12 LT LTEP15725253.7T patent/LT3143011T/lt unknown
- 2015-05-12 PL PL15725253T patent/PL3143011T3/pl unknown
- 2015-05-12 CA CA2948721A patent/CA2948721C/en active Active
- 2015-05-12 JP JP2016567651A patent/JP6529986B2/ja active Active
- 2015-05-12 AU AU2015261008A patent/AU2015261008B2/en active Active
- 2015-05-12 DK DK15725253.7T patent/DK3143011T3/da active
- 2015-05-12 PT PT157252537T patent/PT3143011T/pt unknown
- 2015-05-12 MX MX2016014615A patent/MX2016014615A/es active IP Right Grant
- 2015-05-12 KR KR1020167034871A patent/KR102530129B1/ko active IP Right Grant
-
2016
- 2016-01-26 US US15/006,997 patent/US10076581B2/en active Active
- 2016-11-01 IL IL248692A patent/IL248692B/en active IP Right Grant
-
2018
- 2018-07-31 US US16/050,453 patent/US10675367B2/en active Active
-
2019
- 2019-05-14 AU AU2019203369A patent/AU2019203369B2/en active Active
- 2019-05-15 JP JP2019091813A patent/JP6681498B2/ja active Active
- 2019-12-22 IL IL271631A patent/IL271631B/en active IP Right Grant
-
2020
- 2020-06-08 US US16/895,352 patent/US11504440B2/en active Active
-
2021
- 2021-04-22 HR HRP20210641TT patent/HRP20210641T1/hr unknown
-
2022
- 2022-11-18 US US18/056,856 patent/US20230218782A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210641T1 (hr) | Deuterirani heterociklični spojevi i njihova uporaba kao sredstva za kontrastiranje | |
| HRP20170857T1 (hr) | Derivati stirilpiridina i njihova uporaba za vezanje i snimanje amiloidnih naslaga | |
| JP2017515856A5 (hr) | ||
| Kemppainen et al. | Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease | |
| Gulyás et al. | Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C] vinpocetine | |
| Maeda et al. | In vivo positron emission tomographic imaging of glial responses to amyloid-β and tau pathologies in mouse models of Alzheimer's disease and related disorders | |
| WO2015191506A3 (en) | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles | |
| Ory et al. | PET radioligands for in vivo visualization of neuroinflammation | |
| JP7397492B2 (ja) | 診断のための二環式化合物 | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| JP2008519282A (ja) | アルツハイマー病治療薬をスクリーニングするための画像診断モダリティー | |
| Lee et al. | Age dependency of mGluR5 availability in 5xFAD mice measured by PET | |
| ES2536526T3 (es) | Método para diagnóstico | |
| Sabbagh et al. | Alzheimer's disease biomarkers: correspondence between human studies and animal models | |
| JP2014515364A5 (hr) | ||
| HRP20221098T1 (hr) | Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 | |
| Beaurain et al. | Innovative molecular imaging for clinical research, therapeutic stratification, and nosography in neuroscience | |
| Mathews et al. | Dose‐dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [11C] ABP688 PET imaging | |
| Hwang et al. | Initial characterization of a PDE10A selective positron emission tomography tracer [11C] AMG 7980 in non-human primates | |
| Bang et al. | PET imaging of dopamine transporters with [18F] FE-PE2I: Effects of anti-Parkinsonian drugs | |
| MA50098A (fr) | Procédés de détection du récepteur 1 des folates dans un échantillon provenant d'un patient | |
| Levigoureux et al. | Binding of the PET radiotracer [18F] BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice | |
| Salabert et al. | Radiolabeling of [18F]-fluoroethylnormemantine and initial in vivo evaluation of this innovative PET tracer for imaging the PCP sites of NMDA receptors | |
| Elo et al. | Folate receptor-targeted positron emission tomography of experimental autoimmune encephalomyelitis in rats | |
| Cascini et al. | Neurological applications for myocardial MIBG scintigraphy |